Browse the evidence

A higher Triglyceride-Glucose (TyG) index is independently associated with an increased incidence of atherosclerotic cardiovascular diseases (ASCVD), coronary artery disease (CAD), and stroke in individuals without baseline ASCVD.

If you are getting standard blood work, ask for your fasting glucose and triglyceride levels. You can calculate your TyG index using the formula: ln[triglycerides (mg/dL) × fasting plasma glucose (mg/dL) / 2]. A higher result indicates higher insulin resistance and a statistically higher risk for heart disease and stroke, even if your cholesterol looks normal. Discuss this with your doctor as part of a broader cardiovascular risk assessment.

EPA-only prescription omega-3s (Icosapent Ethyl) do not raise LDL cholesterol in patients with very high triglycerides, whereas EPA+DHA combinations may increase LDL-C by 15-36%.

If you are taking prescription omega-3s for high triglycerides, ask your doctor if your medication contains only EPA or both EPA and DHA. EPA-only options (like Vascepa) do not raise your LDL ('bad') cholesterol, whereas combinations (like Lovaza) might increase it by 15-36%. This distinction is important for your overall cardiovascular risk.

mTORC1 signaling is the central regulator of skeletal muscle mass, acting as a dual controller that promotes hypertrophy through protein synthesis and prevents atrophy by inhibiting catabolic pathways.

To maximize muscle growth, you must activate the mTOR pathway. This is achieved through resistance training (mechanical load), adequate protein intake (amino acids), and growth factors like IGF-1. Conversely, conditions that suppress mTOR (like severe caloric restriction, aging-related sarcopenia, or high cortisol) will hinder muscle maintenance. Prioritize resistance exercise and sufficient protein to keep this signaling pathway active.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, achieves superior glycemic control and weight loss compared to selective GLP-1 agonists by leveraging imbalanced receptor engagement and biased GLP-1 signaling that favors cAMP generation over beta-arrestin recruitment.

Tirzepatide is a once-weekly injection for Type 2 Diabetes that works by activating both GIP and GLP-1 receptors. It is designed to maximize blood sugar control and weight loss while minimizing the stomach side effects often seen with other GLP-1 drugs. Clinical trials show significant improvements in blood sugar and weight loss, particularly at higher doses.

Obesity is fundamentally a state of chronic low-grade systemic inflammation driven by adipose tissue dysfunction, where an expansion of visceral fat leads to a shift from anti-inflammatory M2 macrophages to pro-inflammatory M1 macrophages, resulting in elevated levels of cytokines like TNF-alpha, IL-6, and resistin.

Recognize that obesity involves a biological inflammatory state, not just excess calories. This understanding shifts the focus from simple willpower to managing inflammation through medical and lifestyle interventions. While the paper highlights the problem, it notes that caloric restriction and regular exercise are effective interventions to reduce this inflammation and metabolic dysfunction.

GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) by 14% and all-cause mortality by 12% in patients with type 2 diabetes.

If you have Type 2 Diabetes and are at high risk for heart disease, ask your doctor about GLP-1 receptor agonists (like liraglutide or semaglutide). These medications have been shown to significantly reduce the risk of heart attacks, strokes, and death, in addition to helping with blood sugar control and weight loss.

Metformin reduces all-cause mortality by 36% and heart attack incidence by 39% in overweight patients with newly diagnosed type 2 diabetes without established cardiovascular disease.

If you have recently been diagnosed with Type 2 Diabetes and are overweight, metformin is likely your first medication. It not only helps control blood sugar but has been shown to significantly reduce the risk of heart attacks and death.

Non-alcoholic fatty liver disease (NAFLD) is associated with a 2- to 3-fold increased risk of developing type 2 diabetes (T2D), driven by hepatic insulin resistance, impaired beta-cell function, and lipotoxicity.

If you have been diagnosed with NAFLD, recognize it as a significant warning sign for type 2 diabetes. The presence of liver fat indicates underlying insulin resistance and beta-cell stress. Prioritize interventions that improve insulin sensitivity, such as weight loss and exercise, to mitigate this elevated risk.

Short-term aerobic exercise (as little as 4 days) significantly improves postprandial lipid profiles, reducing non-fasting triglycerides and LDL remnants.

You don't need to wait months to see benefits. Just 4 days of moderate exercise can help your body clear fats from your blood after meals, reducing heart disease risk. You can do this in one session or spread out over the day.

Inulin-propionate ester (IPE) supplementation reduces systemic proinflammatory interleukin-8 (IL-8) levels in adults with overweight and obesity, an effect not observed with inulin alone.

For those managing obesity, IPE supplementation may offer an anti-inflammatory benefit by lowering IL-8, a marker linked to insulin resistance. This effect was specific to IPE and not seen with standard inulin, suggesting the targeted delivery of propionate plays a unique role in reducing systemic inflammation.

PPARgamma activation via thiazolidinediones (TZDs) like rosiglitazone and pioglitazone induces a metabolically beneficial shift in lipid repartitioning from visceral and ectopic storage (liver, muscle) to subcutaneous adipose tissue.

If you are prescribed a TZD (like pioglitazone) for diabetes, understand that any weight gain is likely shifting from dangerous visceral/organ fat to safer subcutaneous fat, which is metabolically protective.

Adiponectin levels are inversely correlated with visceral adipose tissue mass and obesity, and low levels are associated with insulin resistance, hypertension, and cardiovascular disease, while high levels may have protective anti-atherogenic effects.

Maintaining healthy adiponectin levels, often associated with lower body fat and physical activity, may protect against cardiovascular disease and insulin resistance. Strategies that improve insulin sensitivity may help maintain higher adiponectin levels.

High-sensitivity C-reactive protein (hsCRP) levels are positively correlated with BMI and glycated hemoglobin, and elevated hsCRP (>3 mg/L) is an independent risk factor for the development of diabetic microangiopathy and cardiovascular disease.

Monitoring hsCRP levels can help assess cardiovascular and diabetic risk in obese individuals. Lowering inflammation through weight management and healthy lifestyle choices may reduce hsCRP levels and associated risks.

Women with PCOS have an increased risk of impaired glucose tolerance and type 2 diabetes regardless of age and BMI, necessitating routine glycaemic assessment.

If you have PCOS, you need to get your blood sugar checked regularly, even if you are thin. The condition itself raises your risk for diabetes, independent of your weight. Do not skip these tests because you feel healthy or look fit.

Women with PCOS are at increased risk for cardiovascular disease and mortality, requiring lipid and blood pressure monitoring regardless of age or BMI.

You need to have your blood pressure and cholesterol checked regularly, even if you are young and feel fine. PCOS increases your risk of heart disease and stroke. This is a standard part of managing PCOS, not just for older women.

Testosterone replacement therapy (TRT) reliably improves global sexual function (libido, erectile function, sexual satisfaction) in men with functional hypogonadism in the short term.

If you are an older man with confirmed low testosterone and sexual issues (low libido, erectile dysfunction), TRT (specifically starting with transdermal gel) is the recommended treatment to improve sexual function. However, you must be screened for prostate health first. Do not expect TRT to fix weight, diabetes, or bone density issues. If you want children, do not take TRT; ask about gonadotrophin therapy instead.

EPA reduces cardiovascular risk through multiple mechanisms including lowering triglycerides, reducing inflammation, stabilizing cell membranes, and improving endothelial function, distinct from DHA.

EPA works by lowering triglycerides, reducing inflammation, and stabilizing cell membranes, which together protect the heart.

Time-restricted eating (TRE), defined as restricting daily caloric intake to a consistent 8–12 hour window, prevents and manages chronic metabolic diseases by aligning nutrient intake with circadian rhythms, independent of caloric restriction.

Restrict your daily food intake to an 8–12 hour window each day. For example, eat all your meals between 8 AM and 4 PM, or 10 AM and 6 PM. Try to keep this window consistent every day. You do not need to count calories or restrict the amount of food you eat, but aligning your eating with your body's natural clock helps regulate blood sugar and metabolism.

Vitamin D signaling in innate immune cells (macrophages/dendritic cells) stimulates the intracrine synthesis of 1,25-dihydroxyvitamin D, which directly induces the expression of antimicrobial proteins (cathelicidin, beta-defensin 2) and enhances autophagy to combat intracellular pathogens like Mycobacterium tuberculosis.

Ensure your Vitamin D levels are sufficient, as the immune system needs this nutrient to produce antimicrobial proteins that fight bacteria and viruses. This is not just about bone health; your immune cells actively use Vitamin D to fight infections. If you are deficient, your immune cells cannot effectively produce these protective proteins, regardless of how much you take.

Vitamin D signaling suppresses proinflammatory T helper 1 (Th1) and Th17 cells while inducing immunotolerogenic T-regulatory (Treg) responses, thereby modulating adaptive immunity and reducing inflammation.

If you have an autoimmune condition or chronic inflammation, maintaining adequate Vitamin D levels may help regulate your immune system by reducing harmful inflammation and promoting tolerance. However, do not expect it to cure these conditions, as clinical trials show only modest effects.

Women with PCOS have a significantly higher prevalence of impaired glucose tolerance (IGT) and type 2 diabetes (T2DM) compared to women without PCOS, with the magnitude of risk varying by ethnicity.

If you have PCOS, you are at a significantly higher risk for pre-diabetes and type 2 diabetes than women without PCOS, regardless of your weight. You should undergo regular screening (like an OGTT) as recommended by your doctor, rather than waiting for symptoms to appear.

Low circulating glycine levels are consistently associated with obesity, type 2 diabetes, and non-alcoholic fatty liver disease, and prospective studies indicate that decreased plasma glycine is a strong predictive factor for incident glucose intolerance and type 2 diabetes.

If you have obesity or type 2 diabetes, your blood glycine levels are likely lower than average, which is linked to higher insulin resistance. While eating more glycine-rich foods (like vegetable proteins) might help, the root cause involves how your body makes and uses glycine, influenced by your gut bacteria. Focus on overall metabolic health improvements (weight loss, exercise) which are associated with improved glycine concentrations.

The 10,12 CLA isomer is primarily responsible for the fat-loss effects in animal models but causes insulin resistance in humans, whereas the 9,11 isomer may have different metabolic effects.

Most CLA supplements contain a mix of isomers, but the 10,12 isomer is the one that reduces fat in animals but causes insulin resistance in humans. If you take CLA, you are likely consuming this isomer, which may harm your metabolic health.

Obesity superimposed on aging exacerbates chronic low-grade inflammation (inflammaging), which drives insulin resistance and increases the risk of age-related diseases such as type-2 diabetes, rheumatoid arthritis, and cognitive impairment.

If you are older and carrying extra weight, your body is likely in a state of chronic, low-grade inflammation that increases your risk for diabetes, heart disease, and cognitive decline. This isn't just about appearance; it's a biological process. Managing this risk involves addressing the underlying inflammation and metabolic health, not just weight loss alone.